17/12/19 -"We have hiked our estimates on account of: 1. Faster than expected growth in the acquired Osiris business, which will result in a material uplift in the performance of the wound care business 2. ..."
Pages
62
Language
English
Published on
17/12/19
You may also be interested by these reports :
28/01/26
Getinge reported a soft Q4, with net sales and adjusted EBITA missing expectations and organic growth slowing to 1.2%. Order momentum also eased, ...
22/01/26
CZM’s Q1 FY 2025-26 preliminary release fell short of market expectations. Sales and profitability were adversely affected by both external and ...
19/01/26
Drägerwerk has delivered solid FY25 preliminary numbers. The key surprise was EBIT, which beat consensus by c.18%, reflecting better gross margins ...
15/01/26
In late-2024, when we last teased the story of DiaSorin (BUY; Italy), a family-owned in-vitro diagnostic company specialising in immunodiagnostics ...